Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Allogeneic human chondrocyte is an emerging therapy, which can be used for cartilage repair and other indications. Currently, very few market players are developing these therapies, wherein the studies are in clinical trial phase and are expected to soon receive approval from the regulatory agencies. For instance, Invossa, from Kolon TissueGene, Inc., is expected to be the world’s first cell-and-gene therapy for osteoarthritis. This therapy is going to be a cartilage cells extracted from human cartilage (first fluid of HC) and transformed cells with TGF-β1 (second fluid of TC) by the ratio of 3:1. The product is currently in phase 3 clinical trial phase. This is expected to create lucrative opportunity for players to develop such therapies in the near future.

The Europe allogeneic human chondrocyte market is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% during the forecast period (2026-2027).

Figure 1. Europe Allogeneic Human Chondrocyte Market Share (%) in Terms of Value, By Country, 2027

Europe Allogeneic Human Chondrocyte  | Coherent Market Insights

Rising incidence of falls and knee cartilage injuries is expected to propel the market growth during the forecast period

Increasing cases of falls and knee cartilage injuries is a major factor that is expected to propel growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for fall related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway.

Figure 2. Europe Allogeneic Human Chondrocyte Market Share (%), by Application, 2027

Europe Allogeneic Human Chondrocyte  | Coherent Market Insights

Increasing prevalence of musculoskeletal system disorders is expected to propel the market growth over the forecast period

Increasing cases of musculoskeletal system disorders is expected to drive the market growth during the forecast period. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017, was as follows:

 
Country Prevalence of Musculoskeletal Conditions
England 15,899,000
Scotland 1,525,000
Northern Ireland 487,200
Wales 887,000

Europe Allogeneic Human Chondrocyte Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is affecting clinical trials, drastically. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.

request-sample

Europe Allogeneic Human Chondrocyte Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2020:  
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 10.2% 2027 Value Projection: US$ 3,440.5 Mn
Geographies covered:
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Segments covered:
  • By Application: Osteoarthritis, Musculoskeletal System Disorders, Others.
  • By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers.
Companies covered:

Kolon TissueGene, Inc., and ISTO Technologies Inc.

Growth Drivers:
  • The increasing prevalence of musculoskeletal system disorder
  • The increasing incidence of falls and knee cartilage injuries
Restraints & Challenges:
  • High cost of research and development activities
  • Disadvantages of allogeneic transplantation

Furthermore, ongoing clinical trials are being conducted by healthcare facilities and researchers using the following safety measures:

  • The healthcare providers are obtaining patient consent through phone or video conferences. According to a survey conducted by Medidata Solutions, Inc. on April 23, 2020, 45% of the respondents opted for virtual/telemedicine for consultancy
  • Patients receive a phone call for the screening of COVID-19 symptoms before they schedule in-person visits
  • The assessment of the studies are being done in single outpatient areas

Europe Allogeneic Human Chondrocyte Market Restraints:

As the research for human allogeneic chondrocyte is ongoing and products are majorly in the development phase, the research cost and procedures are considerably high and tedious, which can affect the development of such products and is expected to hinder growth of the market.

Moreover, the disadvantages of allogeneic transplantation as compared to autologous transplantation is expected to limit the adoption of allogeneic transplantation, thereby hindering the Europe allogeneic human chondrocyte market growth.

Key Players

Major players operating in the Europe allogeneic human chondrocyte market include Kolon TissueGene, Inc. and ISTO Technologies Inc.

Allogeneic human chondrocyte cell therapy is anticipated to be a good alternative to autologous chondrocyte implantation in the near future. Increasing product approvals by regulatory authorities is expected to fuel the market growth over the forecast period. For instance, in July 2017, Kolon TissueGene, Inc. received the South Korea Ministry of Food & Drug Safety (MFDS) for Invossa-K Inj. The product is currently available in the South Korean market and is marketed by Mundipharma and Kolon Pharmaceuticals.

Market Dynamics

Most of the pharmaceutical manufacturers operating in the Europe allogeneic human chondrocyte market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and agreements to strengthen their market presence and expand its geographical footprint. In June, Kolon TissueGene, Inc., a manufacturer and developer of advanced cell and gene therapies, announced the extension of license agreement with Kolon Life Science, Inc., for the sales of Invossa-K Inj, a cell and gene therapy for knee osteoarthritis. The agreement is expected to expand the geographical footprint of Kolon Life Science, Inc. in the Middle East region with the grant of license for Saudi Arabia and United Arab Emirates (UAE) by the year 2024.

Key features of the study:

  • This report provides in-depth analysis of the Europe allogeneic human chondrocyte market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Europe allogeneic human chondrocyte market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Kolon TissueGene, Inc. and ISTO Technologies Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
  • The Europe allogeneic human chondrocyte market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe allogeneic human chondrocyte market

Detailed Segmentation:

  • Europe Allogeneic Human Chondrocyte Market, By Application:
    • Osteoarthritis
    • Musculoskeletal System Disorders
    • Others
  • Europe Allogeneic Human Chondrocyte Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
  • Europe Allogeneic Human Chondrocyte Market, By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Company Profiles
    • Kolon TissueGene, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
  • ISTO Technologies Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Application
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Europe Allogeneic Human Chondrocyte Market – Impact of Coronavirus (Covid-19) Pandemic
    • Post COVID-19 Market Scenario
    • Clinical Trial Analysis
    • Demand Supply Impact  
  5. Europe Allogeneic Human Chondrocyte Market, By Application, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Osteoarthritis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Musculoskeletal System Disorders
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Europe Allogeneic Human Chondrocyte Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ambulatory Surgical Centers
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Europe Allogeneic Human Chondrocyte Market, By Country, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Country, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Country, 2017–2027
    • Germany
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • U.K.
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • France
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • Italy  
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • Spain
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • Russia
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
    • Rest of Europe
      • Market Size and Forecast, By Application, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Kolon TissueGene, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • ISTO Technologies Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
        • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 20 figures on “Allogeneic Human Chondrocyte Market” –Europe forecast to 2027

Frequently Asked Questions

The Europe allogeneic human chondrocyte market size is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% between 2026 and 2027.
The increasing prevalence of musculoskeletal system disorders, and the rising incidence of falls and knee cartilage injuries are driving the Europe allogeneic human chondrocyte market growth.
The osteoarthritis segment is expected to hold major market share in 2027, owing to increasing prevalence of osteoarthritis.
Germany allogeneic human chondrocyte market is expected to generate highest revenue share in 2027.
Major factors hampering growth of the market are high cost of research and development activities, and disadvantages of allogeneic transplantation.
Major players operating in the Europe allogeneic human chondrocyte market include Kolon TissueGene, Inc. and ISTO Technologies Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner